Compass Therapeutics, Inc.

Analysis for Ticker: CMPX

Compass Therapeutics Inc is a bio-pharmaceutical company that develops antibody therapies aimed at the immune system and the way tumors grow to treat cancer. While it claims to be finding a cure, the math reveals a business that exists solely to burn investor capital, having amassed a historical deficit of 431$ million. They possess 0$ in licensing revenue, meaning they have no income. To stay alive, they simply print new pieces of the company and sell them to the public in a cycle of dilution that is losing 66,5$ million every year. It is like a child selling parts of a borrowed bicycle to buy snacks; by the time the owner notices, the bike is a useless frame and the snacks are gone.